Guidelines For Pharma PLI Scheme To Be Out By March: Secy

New Delhi : The Centre is likely to announce guidelines for the 15,000 crore production-linked incentive (PLI) scheme for the pharma sector in March, pharma secretary S. Aparna said on Thursday.

“Now that we have cabinet approval, we will issue guidelines. Formulating the guidelines will take a month or so. During that time, we will interact with the industry… We might issue the guidelines by the end of March and then call for applications,” she said.

She said the Centre plans to provide two to three months to those willing to apply for the scheme, though the final deadline has still to be decided.

Unlike the earlier PLI scheme, which was aimed at boosting India’s bulk drug security, the new scheme is aimed at encouraging the pharmaceutical industry to move up the value chain by investing in research and development (R&D) of complex generic medicines and novel therapeutics, she said.

“This scheme has a wider range… This is for enhancing manufacturing capabilities, diversifying the product mix to complex generics, patented drugs and going up the value chain, bringing some investment and eventually creating global champions,” she said.

The new scheme is more extensive and could boost pharma production over a longer term, Aparna said.

On Wednesday, the cabinet approved a new PLI scheme for pharma. This scheme will offer a total of 15,000 crore in sops over a nine-year period till March 2029 for an equivalent quantum of investments in biopharmaceuticals, complex generic drugs and patented drugs, gene therapy medicines, orphan drugs as well as in-vitro diagnostics.

The scheme will also cover a wider range of bulk drugs and repurposed medicines.

“The whole idea of moving into higher value, more complex products is to incentivize R&D. Earlier, there was tax breaks for R&D. Now, this one is incentivizing R&D by incentivizing a certain category of products that require certain investments in R&D,” she said.

It is on the lines of another PLI scheme announced last year for over 40 bulk drugs.

  • Related Posts

    • Pharma
    • July 24, 2025
    • 263 views
    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

    Natco Pharma shares slipped 2.5% to Rs 1,009 apiece on the BSE in Thursday’s trade after the company announced its plan to acquire a 35.75% stake in South Africa-based Adcock…

    • Pharma
    • July 22, 2025
    • 329 views
    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    The Directorate General of Foreign Trade ( DGFT ) has notified an extension in the deadline for submitting applications for the export of Pharma Grade Sugar. This was communicated through Trade Notice…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

    Natco Pharma shares dip over 2% after Rs 2,000-crore stake buy in South Africa’s Adcock Ingram

    10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

    10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra